Image source: Getty Images.
What: Despite winning FDA approval of its kidney disease drug Rayaldee last month, shares in Opko Health (NASDAQ: OPK) declined 11.3% in June according to S&P Global Market Intelligence.
Image source: Getty Images.
What: Despite winning FDA approval of its kidney disease drug Rayaldee last month, shares in Opko Health (NASDAQ: OPK) declined 11.3% in June according to S&P Global Market Intelligence.